Bio-Rad Laboratories Statistics
Total Valuation
BIO has a market cap or net worth of $7.93 billion. The enterprise value is $7.84 billion.
| Market Cap | 7.93B |
| Enterprise Value | 7.84B |
Important Dates
The next confirmed earnings date is Tuesday, May 7, 2024, after market close.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BIO has 28.69 million shares outstanding. The number of shares has decreased by -1.93% in one year.
| Shares Outstanding | 28.69M |
| Shares Change (YoY) | -1.93% |
| Shares Change (QoQ) | -1.49% |
| Owned by Insiders (%) | 15.24% |
| Owned by Institutions (%) | 81.70% |
| Float | 19.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 26.00 |
| PS Ratio | 3.01 |
| Forward PS | 2.96 |
| PB Ratio | 0.92 |
| P/FCF Ratio | 36.86 |
| PEG Ratio | 1.19 |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.94 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 35.91 |
Financial Position
The company has a current ratio of 5.83, with a Debt / Equity ratio of 0.16.
| Current Ratio | 5.83 |
| Quick Ratio | 4.02 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | 6.43 |
| Interest Coverage | -16.20 |
Financial Efficiency
Return on equity (ROE) is -7.20%.
| Return on Equity (ROE) | -7.20% |
| Return on Assets (ROA) | -5.10% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $332,660 |
| Profits Per Employee | -$79,368 |
| Employee Count | 8,030 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 1.66 |
Taxes
| Income Tax | -212.78M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.35% in the last 52 weeks. The beta is 0.88, so BIO's price volatility has been lower than the market average.
| Beta (1Y) | 0.88 |
| 52-Week Price Change | -41.35% |
| 50-Day Moving Average | 330.01 |
| 200-Day Moving Average | 340.76 |
| Relative Strength Index (RSI) | 25.44 |
| Average Volume (30 Days) | 206,346 |
Short Selling Information
The latest short interest is 564,754, so 1.97% of the outstanding shares have been sold short.
| Short Interest | 564,754 |
| Short Previous Month | 503,408 |
| Short % of Shares Out | 1.97% |
| Short % of Float | 2.83% |
| Short Ratio (days to cover) | 3.22 |
Income Statement
In the last 12 months, BIO had revenue of $2.67 billion and -$637.32 million in losses. Loss per share was -$21.82.
| Revenue | 2.67B |
| Gross Profit | 1.43B |
| Operating Income | 337.80M |
| Pretax Income | -850.10M |
| Net Income | -637.32M |
| EBITDA | -800.67M |
| EBIT | -800.67M |
| Loss Per Share | -$21.82 |
Balance Sheet
The company has $1.61 billion in cash and $1.41 billion in debt, giving a net cash position of $207.31 million or $7.23 per share.
| Cash & Cash Equivalents | 1.61B |
| Total Debt | 1.41B |
| Net Cash | 207.31M |
| Net Cash Per Share | $7.23 |
| Equity / Book Value | 8.74B |
| Book Value Per Share | 304.65 |
| Working Capital | 2.53B |
Cash Flow
In the last 12 months, operating cash flow was $374.94 million and capital expenditures -$156.47 million, giving a free cash flow of $218.47 million.
| Operating Cash Flow | 374.94M |
| Capital Expenditures | -156.47M |
| Free Cash Flow | 218.47M |
| FCF Per Share | $7.48 |
Margins
Gross margin is 53.42%, with operating and profit margins of 12.65% and -23.86%.
| Gross Margin | 53.42% |
| Operating Margin | 12.65% |
| Pretax Margin | -31.82% |
| Profit Margin | -23.86% |
| EBITDA Margin | -29.97% |
| EBIT Margin | -29.97% |
| FCF Margin | 8.18% |
Dividends & Yields
BIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.93% |
| Shareholder Yield | 1.93% |
| Earnings Yield | -7.91% |
| FCF Yield | 2.71% |
Analyst Forecast
The average price target for BIO is $421.67, which is 52.35% higher than the current price. The consensus rating is "Buy".
| Price Target | $421.67 |
| Price Target Difference | 52.35% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on March 8, 2002. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 8, 2002 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
BIO has an Altman Z-Score of 2.66 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.66 |
| Piotroski F-Score | 5 |